PI3K inhibitors

July 2, 2018

Umbralisib Linked to Fewer Side Effects in Advanced Lymphoma and Leukemia Patients, Data Show

News

Umbralisib, an inhibitor of the PI3K delta protein, has a better long-term safety profile than equivalent treatments for advanced leukemia and lymphoma patients, those whose cancer failed to respond to multiple therapy ... Read more

May 3, 2017May 3, 2017

EMA Grants Orphan Drug Designation for PQR309 Therapeutic In Diffuse Large B-Cell Lymphoma

News

The European Medicines Agency (EMA) has granted Swiss pharmaceutical firm PIQUR Therapeutics orphan drug designation for PQR309 to treat patients with diffuse large B-cell lymphoma (DLBCL). Claudia Pluess, the company’s senior ... Read more

May 2, 2016May 2, 2016

New PI3K Delta Inhibitor to Treat Blood Cancers Shows Promise in Early Clinical Study

News

MEI Pharma recently presented promising clinical results from a new oral phosphatidylinositol 3 kinase (PI3K) delta inhibitor, ME-401, that may improve the therapeutic window in cancer patients compared to other PI3K ... Read more